中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

668 records (took 0.032 seconds)

    AGGLUTINATION-BASED METHOD FOR FAST DETECTION, ISOLATION AND QUANTIFICATION OF APOPTOTIC CELLS
    32.
    发明申请
    AGGLUTINATION-BASED METHOD FOR FAST DETECTION, ISOLATION AND QUANTIFICATION OF APOPTOTIC CELLS 审中-公开
    用于快速检测，分离和定量细胞的基于AGAGUTINATION的方法

    公开(公告)号：WO2007053654A3

    公开(公告)日：2008-01-31

    申请号：PCT/US2006042582

    申请日：2006-10-31

    Applicant: CEDARS SINAI MEDICAL CENTER ,  STOIKA ROSTYSLAV ,  BILYY ROSTYSLAV ,  ANTONYUK VOLODYMYR

    Inventor： STOIKA ROSTYSLAV ,  BILYY ROSTYSLAV ,  ANTONYUK VOLODYMYR

    IPC: G01N33/53

    CPC classification number: G01N33/56966 ,  G01N2333/42 ,  G01N2510/00

    Abstract: The present invention relates to methods and kits for the detection, isolation and quantification of apoptotic cells based on the apoptotic cells' increased expression of alpha-D-mannose and/or beta-D-galactose containing glycoproteins. Lectins that bind to alpha-D-mannose and beta-D-galactose-rich glycoconjugates are used in the methods and kits for agglutination tests for the detection, isolation and quantification of apoptotic cells. Lectins may be used to stimulate the agglutination of cells and apoptosis may be detected by assessing the concentration of lectins required to agglutinate a cell population and comparing the concentration to predetermined values for intact cells and cells in various stages after induction of apoptosis.

    Abstract translation: 本发明涉及用于基于凋亡细胞增加的含有α-D-甘露糖和/或含有β-D-半乳糖的糖蛋白的表达来检测，分离和定量凋亡细胞的方法和试剂盒。 结合α-D-甘露糖和β-D-半乳糖的糖缀合物的凝集素用于用于细胞凋亡细胞的检测，分离和定量的凝集试验的方法和试剂盒。 可以使用凝集素刺激细胞的凝集，并且通过评估凝集细胞群所需的凝集素的浓度并将其浓度与诱导凋亡后各个阶段的完整细胞和细胞的浓度进行比较可以检测细胞凋亡。

    BIR DOMAIN BINDING COMPOUNDS
    33.
    发明申请
    BIR DOMAIN BINDING COMPOUNDS 审中-公开
    双畴结合化合物

    公开(公告)号：WO2007101347A1

    公开(公告)日：2007-09-13

    申请号：PCT/CA2007/000371

    申请日：2007-03-07

    Applicant: AEGERA THERAPEUTICS INC. ,  JAQUITH, James

    Inventor： JAQUITH, James

    IPC: C07D281/10 ,  A61K31/55 ,  A61K31/554 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07D223/04 ,  C07D267/14 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  G01N33/567 ,  G01N33/58

    CPC classification number: A61K45/06 ,  C07D223/10 ,  C07D223/16 ,  C07D267/14 ,  C07D281/10 ,  C07K5/0806 ,  G01N2500/02 ,  G01N2510/00

    Abstract: Disclosed herein are compounds as resented by Formula (I): wherein R 1 ,R 2 , R 3 , R 4 , n, W, A, and Q are as defined herein. The compounds of formula (I) are useful as antagonists of the IAPs via binding to BIR domain. The compounds are useful for application to the cells or subjects afflicted with or having a predisposition towards developing a particular disease state, which is characterized by insufficient apoptosis. Thus, the compounds and compositions thereof are used to treat cellular proliferative diseases/disorders, which include, cancer, autoimmune diseases, inflammatory disorders, proliferation induced post medical procedures, etc. The compounds may also be useful in the treatment of diseases in which there is a defect in the programmed cell-death or the apoptotic machinery, such as multiple sclerosis, artherosclerosis, inflammation, autoimmunity, etc.

    Abstract translation: 本文公开的是式（I）表示的化合物：其中R 1，R 2，R 3，R 4， SUP>，n，W，A和Q如本文所定义。 通过结合BIR结构域，式（I）化合物可用作IAP的拮抗剂。 该化合物可用于施用于患有或具有发展特定疾病状态的倾向的细胞或受体，其特征在于细胞凋亡不足。 因此，其化合物及其组合物用于治疗细胞增殖性疾病/病症，包括癌症，自身免疫性疾病，炎性病症，增殖诱导的后医疗程序等。化合物也可用于治疗其中存在的疾病 是程序性细胞死亡或凋亡机制的缺陷，如多发性硬化，动脉粥样硬化，炎症，自身免疫等。

    METHODS AND COMPOSITIONS FOR MODULATING CELL DEATH WITH SURVIVAL-OR DEATH KINASES OR PHOSPHATASES
    34.
    发明申请
    METHODS AND COMPOSITIONS FOR MODULATING CELL DEATH WITH SURVIVAL-OR DEATH KINASES OR PHOSPHATASES 审中-公开
    用于调节存活或死亡动物或磷酸酶的细胞死亡的方法和组合物

    公开(公告)号：WO2006091701A3

    公开(公告)日：2007-07-26

    申请号：PCT/US2006006346

    申请日：2006-02-22

    Applicant: HARVARD COLLEGE ,  MACKEIGAN JEFFREY P ,  MURPHY LEON O ,  BLENIS JOHN

    Inventor： MACKEIGAN JEFFREY P ,  MURPHY LEON O ,  BLENIS JOHN

    IPC: G01N33/50 ,  C12Q1/42 ,  C12Q1/48

    CPC classification number: G01N33/5017 ,  C12Q1/42 ,  C12Q1/485 ,  G01N2333/91215 ,  G01N2500/00 ,  G01N2510/00

    Abstract: The invention relates to methods for modulating cell death and cell survival and for modulating the sensitivity of cells towards agents that modulate cell death or cell survival. The invention also relates to the identification of kinases and phosphatases that promote cell survival or cell death. The invention further relates to methods for screening compounds that modulate the activity, expression and/or protein-protein interactions of cell survival or cell death-promoting kinases and phosphatases. Accordingly, kinases and/or phosphatases that modulate cell proliferation and death may serve as therapeutic targets for the development of new cancer treatments.

    Abstract translation: 本发明涉及调节细胞死亡和细胞存活并调节细胞对调节细胞死亡或细胞存活的药物敏感性的方法。 本发明还涉及促进细胞存活或细胞死亡的激酶和磷酸酶的鉴定。 本发明还涉及用于筛选调节细胞存活或细胞死亡促进激酶和磷酸酶的活性，表达和/或蛋白质 - 蛋白质相互作用的化合物的方法。 因此，调节细胞增殖和死亡的激酶和/或磷酸酶可以作为开发新的癌症治疗的治疗靶点。

    ASSAYS AND METHODS USING BIOMARKERS
    35.
    发明申请
    ASSAYS AND METHODS USING BIOMARKERS 审中-公开
    使用生物标记的测定和方法

    公开(公告)号：WO2007022214A2

    公开(公告)日：2007-02-22

    申请号：PCT/US2006031894

    申请日：2006-08-15

    Applicant: GENENTECH INC ,  WAGNER KLAUS W

    Inventor： WAGNER KLAUS W

    IPC: G01N33/50

    CPC classification number: G01N33/574 ,  A61K38/1703 ,  A61K38/19 ,  C12Q1/37 ,  C12Q1/6834 ,  C12Q1/686 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/5023 ,  G01N2333/91102 ,  G01N2510/00

    Abstract: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of GalNac-T related molecules, such as GalNac-T14 or GalNac-T3, is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Kits and articles of manufacture are also provided.

    Abstract translation: 提供检查哺乳动物组织或细胞样品中一种或多种生物标志物的表达的方法和试验。 根据所公开的方法和测定，GalNac-T相关分子如GalNac-T14或GalNac-T3的表达的检测是预测或指示组织或细胞样品对凋亡诱导剂如Apo2L敏感 / TRAIL和抗DR5激动剂抗体。 还提供了工具包和制品。

    SELECTIVE APOPTOTIC INDUCTION IN CANCER CELLS INCLUDING ACTIVATION OF PROCASPASE-3
    39.
    发明申请
    SELECTIVE APOPTOTIC INDUCTION IN CANCER CELLS INCLUDING ACTIVATION OF PROCASPASE-3 审中-公开
    癌细胞中的选择性诱导诱导，包括细胞因子-3的激活

    公开(公告)号：WO2006128173A2

    公开(公告)日：2006-11-30

    申请号：PCT/US2006020910

    申请日：2006-05-26

    Applicant: UNIV ILLINOIS ,  HERGENROTHER PAUL J ,  PUTT KARSON S ,  CHEN GRACE W ,  PEARSON JENNIFER M

    Inventor： HERGENROTHER PAUL J ,  PUTT KARSON S ,  CHEN GRACE W ,  PEARSON JENNIFER M

    IPC: A61K31/495

    CPC classification number: A61K31/495 ,  C07D295/15 ,  C12Q1/37 ,  G01N33/502 ,  G01N33/574 ,  G01N2333/96466 ,  G01N2510/00 ,  G01N2800/52

    Abstract: Compounds and related methods for synthesis, and the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3, and particular embodiments are capable of direct activation of procaspase-3 and procaspase-7 to the effector forms of caspase-3 and caspase-7. Procaspase-3 levels can vary among cancer cell types; several types have relatively high levels and can have increased susceptibility to chemotherapy by compounds and methods herein. Therapeutic applications are relevant for a variety of cancer conditions and cell types, e.g. breast, lung, brain, colon, renal, adrenal, melanoma, and others.

    Abstract translation: 公开了合成的化合物和相关方法，以及化合物在治疗中用于治疗癌症和选择性诱导细胞凋亡的用途。 公开了与胱天蛋白酶（procaspase）如procaspase-3的修饰有关的化合物，特定实施方案能够将胱天蛋白酶-3和胱天蛋白酶-7的效应物形式直接活化于胱天蛋白酶-3和胱天蛋白酶-7。 Procaspase-3水平可能因癌细胞类型而异; 几种类型具有相对较高的水平，并且可以通过本文化合物和方法增加对化学疗法的易感性。 治疗应用与各种癌症状况和细胞类型有关，例如， 乳腺，肺，脑，结肠，肾，肾上腺，黑素瘤等。

    SUPERANTIBODY SYNTHESIS AND USE IN DETECTION, PREVENTION AND TREATMENT OF DISEASE
    40.
    发明申请
    SUPERANTIBODY SYNTHESIS AND USE IN DETECTION, PREVENTION AND TREATMENT OF DISEASE 审中-公开
    超敏反应合成和用于检测，预防和治疗疾病

    公开(公告)号：WO2006119291A2

    公开(公告)日：2006-11-09

    申请号：PCT/US2006/016844

    申请日：2006-04-29

    Applicant: INNEXUS BIOTECHNOLOGY INTERNATIONAL LTD. ,  KOHLER, Heinz ,  MULLER, Sybille ,  MORGAN, Alton Charles, Jr.

    Inventor： KOHLER, Heinz ,  MULLER, Sybille ,  MORGAN, Alton Charles, Jr.

    IPC: A61K39/395 ,  G01N33/53 ,  G01N33/574 ,  C07K16/46

    CPC classification number: G01N33/92 ,  A61K41/0042 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6871 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2896 ,  C07K16/3084 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/73 ,  G01N2510/00 ,  G01N2800/323

    Abstract: Superantibodies having enhanced autophilic, catalytic, and/or membrane- penetrating properties are prepared by affinity-based conjugation of a photoactivatable organic molecule to a target immunoglobulin. The photoactivatable organic molecule bears a chromophoric aromatic hydrocarbon moiety, which has affinity for the immunoglobulin. Upon photolysis, the organic molecule is covalently linked to the immunoglobulin. A preferred organic molecule is a peptide and a preferred aromatic hydrocarbon moiety is a tryptophan residue. The photoactivatable organic molecule need not bear a purine, pyrimidine or azido group to effect binding to the immunoglobulin and/or photoactivation. The superantibodies can enhance the potency and expand the targeting range of target antibodies. Autophilic superantibodies can promote apoptosis of target cells and/or enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Exemplary of such diseases are atherosclerosis and cardiovascular disease. Membrane-penetrating superantibodies can prevent apoptosis by binding to intracellular anti-caspase signal proteins. Compositions containing the superantibodies, as well as methods of making and using them, are disclosed.

    Abstract translation: 具有增强的自噬性，催化和/或膜穿透性质的超抗体通过可光活化的有机分子与靶免疫球蛋白的亲和基偶联来制备。 可光活化的有机分子具有对免疫球蛋白具有亲和性的发色芳烃部分。 光解后，有机分子与免疫球蛋白共价连接。 优选的有机分子是肽，优选的芳族烃部分是色氨酸残基。 可光活化的有机分子不需要携带嘌呤，嘧啶或叠氮基以实现与免疫球蛋白的结合和/或光活化。 超抗体可增强靶向抗体的效力并扩大靶向范围。 自噬性超抗体可以促进靶细胞的凋亡和/或增强治疗对抗体治疗反应的疾病或病症的患者的治疗功效。 这些疾病的示例是动脉粥样硬化和心血管疾病。 膜穿透性超抗体可以通过结合细胞内抗半胱天冬酶信号蛋白来预防凋亡。 公开了含有超抗体的组合物，以及制备和使用它们的方法。

Patent Agency Ranking